In vitro biological evaluation of the synthesized compounds 6a–g, 7a–g, and 8a–g MIC (μg mL−1)a.
| Entry | Antifungal activity | Anti TB MTB H37Rv | DPPH IC50 (μg mL−1) | ||||
|---|---|---|---|---|---|---|---|
| CA | FO | AF | AN | CN | |||
| 6a | 87.5 | 100 | 175 | 125 | 187.5 | 25 | 55.37 |
| 6b | 150 | 125 | 150 | 150 | * | >25 | 26.64 |
| 6c | 175 | 200 | 150 | 175 | 200 | 25 | 20.54 |
| 6d | 187.5 | 162.5 | 187.5 | 200 | * | >25 | * |
| 6e | 200 | * | * | 187.5 | 175 | >25 | 29.64 |
| 6f | 150 | 175 | 162.5 | 200 | * | 25 | 74.28 |
| 6g | 162.5 | 175 | 175 | 187.5 | 150 | >25 | 74.41 |
| 7a | 137.5 | 125 | 100 | 137.5 | 125 | >25 | 11.44 |
| 7b | 175 | 200 | 100 | 175 | 200 | >25 | 16.79 |
| 7c | * | * | 200 | * | 175 | >25 | 12.30 |
| 7d | 200 | 175 | 150 | 150 | 200 | >25 | 19.46 |
| 7e | 175 | 175 | 200 | * | * | >25 | 70.33 |
| 7f | 100 | 150 | 100 | 100 | 75 | >25 | * |
| 7g | 75 | 100 | 87.5 | 100 | 200 | >25 | 49.60 |
| 8a | 25 | 37.5 | 25 | 75 | 75 | >25 | 97.29 |
| 8b | 12.5 | 25 | 25 | 25 | 37.5 | >25 | * |
| 8c | 12.5 | 25 | 25 | 50 | 25 | >25 | 48.02 |
| 8d | 25 | 25 | 37.5 | 25 | 50 | >25 | 22.17 |
| 8e | 50 | 25 | 12.5 | 25 | 12.5 | >25 | 62.01 |
| 8f | 12.5 | 12.5 | 25 | 12.5 | 12.5 | >25 | * |
| 8g | 25 | 25 | 12.5 | 25 | 12.5 | >25 | 16.99 |
| MA | 25 | 25 | 12.5 | 25 | 25 | NA | NA |
| INH | NA | NA | NA | NA | NA | 0.1 | NA |
| RIF | NA | NA | NA | NA | NA | 0.2 | NA |
| EMB | NA | NA | NA | NA | NA | 1.56 | NA |
| CIP | NA | NA | NA | NA | NA | 1.56 | NA |
| BHT | NA | NA | NA | NA | NA | NA | 16.47 |
a
CA: Candida albicans; FO: Fusarium oxysporum; AF: Aspergillus flavus; AN: Aspergillus niger and CN: Cryptococcus neoformans. MA: Miconazole, DPPH: 2,2-diphenyl-1-picrylhydrazyl; INH: Isoniazid; RIF: Rifampicin; EMB: Ethambutol; CIP: Ciprofloxacin; BHT: butylated hydroxytoluene; *no activity was observed, NA: not applicable.